Plain-English translation of NCT05839392 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are trying to understand a rare form of acute myeloid leukemia (AML) that involves changes in a gene called MECOM. By studying bone marrow samples from patients with this specific type of leukemia, the team hopes to learn more about how the disease develops at the genetic level — information that could lead to better treatments in the future.
This type of leukemia with MECOM changes is uncommon, and doctors don't yet fully understand what makes it different from other forms of AML. By mapping out the genes and proteins involved, this research could help identify new ways to treat patients with this rare subtype.
You likely qualify if…
You likely don't qualify if…
You would be asked to provide bone marrow samples at the time you enroll in the study, and potentially before and after you receive cancer treatment and if your disease returns. The researchers will analyze these samples in the laboratory to study the genetic makeup of your leukemia cells. There is no experimental medication or treatment — this is a research study designed to gather information that could help future patients.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy
Enrollment target
~24 participants
Started
December 2023
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Paola Fazi
Department of Medicine and Surgery, University of Parma, Parma
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.